Lv3
240 积分 2025-01-12 加入
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
3天前
已完结
METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours
3天前
已完结
Recent Advances in the Synthesis of Acyclic Nucleosides and Their Therapeutic Applications
3天前
已完结
Recent Advances in the Synthesis of Acyclic Nucleosides and Their Therapeutic Applications
3天前
已完结
One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors
3天前
已完结
Base‐Promoted Cycloisomerization for the Synthesis of Oxazoles and Imidazoles
5天前
已关闭
2,3-Dichloro-5,6-dicyano-1,4-benzoquinone-Catalyzed Reactions Employing MnO2 as a Stoichiometric Oxidant
1个月前
已完结
Efficient synthesis of nebularine and vidarabine via dehydrazination of (hetero)aromatics catalyzed by CuSO 4 in water
1个月前
已关闭
Efficient synthesis of nebularine and vidarabine via dehydrazination of (hetero)aromatics catalyzed by CuSO4 in water
1个月前
已关闭
Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations
2个月前
已完结
皖公网安备34019202002308
